temozolomide has been researched along with xanthenes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arcella, A; Battaglia, G; Bonelli, M; Ciceroni, C; De Maria, R; Larocca, LM; Laurenza, M; Mastrantoni, E; Melchiorri, D; Niccolini, C; Nicoletti, F; Pallini, R; Ricci-Vitiani, L; Spinsanti, P; Traficante, A | 1 |
| Beck, J; Behringer, SP; Follo, M; Garrelfs, N; Goeldner, JM; Hannibal, L; Heiland, DH; Hofmann, UG; Joseph, K; Kueckelhaus, J; Maier, JP; Pfeifer, D; Ravi, VM; Schnell, O; Sun, N; von Ehr, J; Walch, AK; Will, P | 1 |
2 other study(ies) available for temozolomide and xanthenes
| Article | Year |
|---|---|
Type-3 metabotropic glutamate receptors regulate chemoresistance in glioma stem cells, and their levels are inversely related to survival in patients with malignant gliomas.
Topics: Amino Acids; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modality Therapy; Dacarbazine; DNA Methylation; Drug Resistance, Neoplasm; Glioblastoma; Humans; Mice; Neoplastic Stem Cells; NF-kappa B; O(6)-Methylguanine-DNA Methyltransferase; Phosphatidylinositol 3-Kinases; Promoter Regions, Genetic; Receptors, Metabotropic Glutamate; RNA, Messenger; Signal Transduction; Survival Rate; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xanthenes | 2013 |
Inhibition of metabotropic glutamate receptor III facilitates sensitization to alkylating chemotherapeutics in glioblastoma.
Topics: Amino Acids; Antineoplastic Agents, Alkylating; Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glioblastoma; Glutamic Acid; Humans; Kinetics; Neoadjuvant Therapy; Receptors, Metabotropic Glutamate; Temozolomide; Tumor Microenvironment; Xanthenes | 2021 |